ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments

Xu, Xinjie; Huang, Shengkang; Xiao, Xinyi; Sun, Qihang; Liang, Xiaoqian; Chen, Sifei; Zhao, Zijing; Huo, Zhaochang; Tu, Sanfang*; Li, Yuhua*南方医科大学; 中国医学科学院; 中国医学科学院北京协和医院
Frontiers in Immunology2021-2-10DOI: 10.3389/fimmu.2020.569117
29被引6阅读
引用收藏
分享

摘要

Chimeric antigen receptor (CAR) T-cell therapy exhibits desirable and robust efficacy in patients with acute lymphoblastic leukemia (ALL). Stimulated by the revolutionized progress in the use of FDA-approved CD19 CAR T cells, novel agents with CAR designs and targets are being produced in pursuit of superior performance. However, on the path from bench to bedside, new challenges emerge. Accessibility is considered the initial barrier to the transformation of this patient-specific product into a commercially available product. To ensure infusion safety, profound comprehension of adverse events and proactive intervention are required. Additionally, resistance and relapse are the most critical and intractable issues in CAR T-cell therapy for ALL, thus precluding its further development. Understanding the limitations through up-to-date insights and characterizing multiple strategies will be critical to leverage CAR T-cell therapy flexibly for use in clinical situations. Herein, we provide an overview of the application of CAR T-cell therapy in ALL, emphasizing the main challenges and potential clinical strategies in an effort to promote a standardized set of treatment paradigms for ALL.

学科与关键词

关键词
CAR T-cellapplicationchallengesaccessadverse eventsresistancerelapseclinical strategies
相关
加载中…
  • CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities
    Ren, Anqi; Tong, Xiqin; Xu, Na; Zhang, Tongcun; Zhou, Fuling*; Zhu, Haichuan*Vaccines, 2023, 11(1): 165.被引 7
  • CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
    Zhang, Xiaomin; Zhu, Lingling; Zhang, Hui; Chen, Shanshan; Xiao, Yang*Frontiers in Immunology, 2022, 13: 927153.被引 47
  • Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies
    Liu, Qianzhen; Liu, Zengping; Wan, Rongxue*; Huang, Wenhua*Cancers, 2022, 14(18): 4452.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2021-02-10
卷期
第 11 卷
页码
569117
DOI
10.3389/fimmu.2020.569117
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
Clinical Research Startup Program of Southern Medical University by High-level University Construction Funding of Guangdong Provincial Department of Education [LC2016ZD027]; Guangdong Science and Technology Department [2017A020215183]; Major Program for Health Medical Collaborative Innovation of Guangzhou [201704020216]; Natural Science Foundation of Guangdong Province, China [2018B030311042]; Frontier Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory [2018GZR110105014]

作者

  • X

    Xu, Xinjie (第一作者)

    southern med univ · chinese acad med sci · fuwai hosp · peking union med coll · 2

  • H

    Huang, Shengkang

    southern med univ · 2

查看全部 10 位作者收起作者
  • X

    Xiao, Xinyi

    southern med univ · 2

  • S

    Sun, Qihang

    southern med univ · 2

  • L

    Liang, Xiaoqian

    southern med univ · 2

  • C

    Chen, Sifei

    southern med univ · 2

  • Z

    Zhao, Zijing

    southern med univ · 2

  • H

    Huo, Zhaochang

    southern med univ · 2

  • T

    Tu, Sanfang (通讯)

    southern med univ

  • L

    Li, Yuhua (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417